Prostatic Hyperplasia Treatment and Cancer Prevention

Treatment of Prostatic Hyperplasia With Topical Papaverine

Status

UNKNOWN

Phases

Early Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03064282

Enrollment

Registered

2017-02-27

Start date

2021-06-30

Completion date

2021-12-01

Last updated

2021-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostatic Hyperplasia

Brief summary

Treatment of patients with prostatic hyperplasia with topical papaverine.

Detailed description

Patients with obstructive voiding and high PSA to be studied for the regression of symptoms and declining PSA.

Interventions

OTHERPlacebo

observation of skin changes if any

DRUGpapaverine

observation of symptoms

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

50 Years to 70 Years

Healthy volunteers

Yes

Inclusion criteria

* patients with symptoms e.g. obstructive voiding, hyperplasia and high PSA

Exclusion criteria

* patients on chemotherapy * abnormal lab values e.g. liver function, GFR and CAD

Design outcomes

Primary

Measure	Time frame	Description
Laboratory tests to measure regression of symptoms	every 4 weeks up to 16 weeks	patients follow-up on regular intervals

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026